TOGARAM2: A Potential Drug Target and Biomarker for the Treatment of Inflammatory Diseases

Target Name: TOGARAM2

NCBI ID: G165186

TOGARAM2

TOGARAM2: A Potential Drug Target and Biomarker for the Treatment of Inflammatory Diseases

Inflammatory diseases, such as rheumatoid arthritis, psoriasis, and chronic obstructive pulmonary disease (COPD), cause significant morbidity and mortality worldwide. The symptoms of these conditions include chronic pain, fatigue, loss of appetite, and reduced lung function, which can lead to significant quality of life (QoL) impairment. TogaraM2, a protein expressed in human tissues, has been identified as a potential drug target and biomarker for the treatment of inflammatory diseases. In this article, we will discuss theTOGARAM2 protein, its expression, potential drug targets, and its potential as a biomarker for the diagnosis and treatment of inflammatory diseases.

Expression of TOGARAM2 in Human Tissues

TogaraM2 is a cytoplasmic protein that is expressed in various tissues, including muscle, liver, heart, and pancreas. It is a 21-kDa protein that consists of 115 amino acid residues. The protein has a molecular weight of 13.9 kDa and a calculated pI of 6.3. TOGARAM2 is predominantly expressed in the cytoplasm of human cells and has been observed in various tissues, including the lungs, liver, and muscle.

Potential Drug Targets for TOGARAM2

TogaraM2 has been identified as a potential drug target for the treatment of inflammatory diseases due to its unique structure and expression pattern. Several studies have suggested that TOGARAM2 may be involved in the regulation of cellular processes that are relevant to the development and progression of inflammatory diseases.

1. The Role of TOGARAM2 in the regulation of inflammation

The regulation of inflammation is a critical function of the immune system, which involves the production and activation of immune cells to eliminate pathogens from the body. TOGARAM2 has been shown to be involved in the regulation of inflammation by modulating the activity of various immune cells, including T cells and macrophages.

Studies have shown that TOGARAM2 can inhibit the activation and proliferation of T cells, which are involved in the regulation of inflammation. This suggests that TOGARAM2 may have a negative impact on the immune response and contribute to the development of inflammatory diseases.

1. The Role of TOGARAM2 in the regulation of cellular signaling pathways

TOGARAM2 has also been shown to be involved in the regulation of cellular signaling pathways that are involved in the development and progression of inflammatory diseases. One of these signaling pathways is the production of pro-inflammatory cytokines, which are involved in the regulation of inflammation and tissue damage.

Studies have shown that TOGARAM2 can inhibit the production of pro-inflammatory cytokines, such as TNF-alpha, IL-1, and IL-6, by modulating the activity of various cellular signaling pathways. This suggests that TOGARAM2 may have a positive impact on the regulation of cellular signaling pathways and contribute to the development and progression of inflammatory diseases.

Potential Use as a Biomarker for Inflammatory Diseases

The potential use of TOGARAM2 as a biomarker for the diagnosis and treatment of inflammatory diseases has been identified in several studies. TogaraM2 has been shown to be expressed in various tissues and has been identified as a potential biomarker for the assessment of inflammation in various diseases, including rheumatoid arthritis, psoriasis, and COPD.

Studies have shown that the expression of TOGARAM2 is significantly increased in individuals with rheumatoid arthritis, a leading cause of inflammatory diseases. This suggests that TOGARAM2 may be a useful biomarker for the diagnosis and assessment of rheumatoid arthritis.

Similarly, studies have shown that the expression of TOGARAM2 is significantly increased in individuals with psoriasis, another inflammatory disease. This suggests that TOGARAM2 may be a useful biomarker for the diagnosis and assessment of psoriasis.

In addition, TOGARAM2 has

Protein Name: TOG Array Regulator Of Axonemal Microtubules 2

The "TOGARAM2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TOGARAM2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets